Mirinda Ann Gormley1, Matthew J Akiyama2, Lior Rennert1, Kerry A Howard1, Brianna L Norton2, Irene Pericot-Valverde3, Sam Muench2, Moonseong Heo1, Alain H Litwin3,4,5. 1. Department of Public Health Sciences, Clemson University, Clemson, South Carolina, USA. 2. Department of Medicine, Division of General Internal Medicine, Albert Einstein College of Medicine, Bronx, New York, USA. 3. Clemson University School of Health Research, Clemson, South Carolina, USA. 4. Department of Medicine, University of South Carolina School of Medicine, Greenville, South Carolina, USA. 5. Department of Internal Medicine, Prisma Health, Greenville, South Carolina, USA.
Abstract
BACKGROUND: Although efforts to treat hepatitis C virus (HCV) in people who inject drugs (PWID) yield high rates of sustained virologic response (SVR), the relationship between successful HCV treatment and health-related quality of life (HRQOL) among PWID is poorly understood. We examined HRQOL changes throughout HCV treatment and post-treatment for PWID achieving SVR. METHODS: Participants included 141 PWID who achieved SVR following HCV treatment onsite at 3 opioid agonist treatment (OAT) clinics in the Bronx, New York. EQ-5D-3L assesses 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), producing an index of HRQOL ranging from 0 to 1. EQ-5D-3L was measured at baseline; 4, 8, and 12 weeks during treatment; and 12 and 24 weeks post-treatment. Linear mixed effects regression models assessed changes in the mean EQ-5D-3L index over time. RESULTS: Mean EQ-5D-3L index baseline was 0.66 (standard error [SE] = 0.02). While over half the population reported no baseline problems with self-care (85.1%), usual activities (56.0%), and mobility (52.5%), at least two-thirds reported problems with pain/discomfort (78.0%) and anxiety/depression (66.0%). Twenty-four weeks post-treatment, proportions reporting pain/discomfort and anxiety/depression decreased by 25.7% and 24.0%, respectively. Mean EQ-5D-3L index significantly improved during treatment (P < .0001), and improvement was sustained following treatment completion, with mean EQ-5D-3L index of 0.77 (SE = 0.02) 12 weeks post-SVR. CONCLUSIONS: HCV treatment led to sustained improvement in HRQOL for PWID on OAT who achieved SVR. Future research is necessary to determine whether improvements in HRQOL can be sustained beyond 12 weeks post-SVR.
BACKGROUND: Although efforts to treat hepatitis C virus (HCV) in people who inject drugs (PWID) yield high rates of sustained virologic response (SVR), the relationship between successful HCV treatment and health-related quality of life (HRQOL) among PWID is poorly understood. We examined HRQOL changes throughout HCV treatment and post-treatment for PWID achieving SVR. METHODS: Participants included 141 PWID who achieved SVR following HCV treatment onsite at 3 opioid agonist treatment (OAT) clinics in the Bronx, New York. EQ-5D-3L assesses 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), producing an index of HRQOL ranging from 0 to 1. EQ-5D-3L was measured at baseline; 4, 8, and 12 weeks during treatment; and 12 and 24 weeks post-treatment. Linear mixed effects regression models assessed changes in the mean EQ-5D-3L index over time. RESULTS: Mean EQ-5D-3L index baseline was 0.66 (standard error [SE] = 0.02). While over half the population reported no baseline problems with self-care (85.1%), usual activities (56.0%), and mobility (52.5%), at least two-thirds reported problems with pain/discomfort (78.0%) and anxiety/depression (66.0%). Twenty-four weeks post-treatment, proportions reporting pain/discomfort and anxiety/depression decreased by 25.7% and 24.0%, respectively. Mean EQ-5D-3L index significantly improved during treatment (P < .0001), and improvement was sustained following treatment completion, with mean EQ-5D-3L index of 0.77 (SE = 0.02) 12 weeks post-SVR. CONCLUSIONS: HCV treatment led to sustained improvement in HRQOL for PWID on OAT who achieved SVR. Future research is necessary to determine whether improvements in HRQOL can be sustained beyond 12 weeks post-SVR.
Authors: Anand Kumthekar; Sarah Shull; Travis I Lovejoy; Benjamin J Morasco; Michael Chang; Jennifer Barton Journal: Int J Rheum Dis Date: 2019-02-06 Impact factor: 2.454
Authors: Sahar Saeed; Erica E M Moodie; Erin Strumpf; John Gill; Alexander Wong; Curtis Cooper; Sharon Walmsley; Mark Hull; Valerie Martel-Laferriere; Marina B Klein Journal: J Viral Hepat Date: 2018-09-27 Impact factor: 3.728
Authors: Irene Pericot-Valverde; Moonseong Heo; Jiajing Niu; Brianna L Norton; Matthew J Akiyama; Linda Agyemang; Alain H Litwin Journal: Open Forum Infect Dis Date: 2020-10-10 Impact factor: 3.835
Authors: Megan E Gray; Elizabeth T Rogawski McQuade; W Michael Scheld; Rebecca A Dillingham Journal: BMC Infect Dis Date: 2018-10-24 Impact factor: 3.090